• Image of Zelboraf medication

    • ZELBORAF

    • QTY 112
    • 240 MG
    • Tablet

VEMURAFENIB (Vem ue RAF e nib) is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat melanoma, a type of skin cancer, and Erdheim-Chester disease.

ZELBORAF Lifestyle Interactions

  • Vemurafenib 240mg, Oral tablet

    • Interaction: Grapefruit juice
    • Severity: Major
    • Notes for Consumers: If you drink grapefruit juice, talk to your health care professional. Taking Vemurafenib and grapefruit or grapefruit juice together may increase the levels of vemurafenib in your body and increase the risk of vemurafenib side effects such as skin rash, liver problems, and change in heart beat or heart rhythms.
    • Notes for Professionals: Avoid the concomitant use of vemurafenib and grapefruit juice; vemurafenib exposure may be increased resulting in an increased risk of adverse events, including QT prolongation.

  • Vemurafenib 240mg, Oral tablet

    • Interaction: Caffeine-containing Foods/Beverages
    • Severity: Mild
    • Notes for Consumers: Side effects from Caffeine may get worse if you take Vemurafenib. Too much Caffeine can cause effects like nausea, nervousness, or sleeplessness. You may need to limit your Caffeine intake. Common foods and beverages containing caffeine include coffee, teas, colas and chocolate. Many non-prescription drugs and diet aids may also contain caffeine.
    • Notes for Professionals: Coadministration of vemurafenib and caffeine increased the caffeine AUC by 2.6-fold. Vemurafenib is a CYP1A2 inhibitor and caffeine is a CYP1A2 substrate. The manufacturer of vemurafenib suggests that concomitant use with agents with narrow therapeutic windows that are metabolized by CYP1A2 is not recommended. Theophylline (or aminophylline), another methylxanthine, is also primarily a CYP1A2 substrate with a narrow therapeutic index. If coadministration cannot be avoided, the manufacturer recommends considering a dose reduction of the concomitant drug; it may also be prudent to monitor for signs and symptoms of theophylline toxicity during coadministration. Some patients may need to reduce intake of caffeine from non-drug sources (e.g., beverages) during treatment to avoid caffeine-related side effects.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.